Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fortress Biotech Inc FBIO

Alternate Symbol(s):  FBIOP

Healthcare Biotechnology
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products and product candidates. The Company markets its various branded dermatology products, Qbrexza, Accutane, Amzeeq, Zilxi, Ximino, Exelderm and Targadox. Qbrexza (glycopyrronium 2.4%) is a medicated cloth towelette for the treatment of primary axillary... see more

Recent & Breaking News (NDAQ:FBIO)

Fortress Biotech to Present at September 2019 Investor Conferences

GlobeNewswire September 5, 2019

Checkpoint Therapeutics to Present at September 2019 Investor Conferences

GlobeNewswire September 4, 2019

Mustang Bio to Present at September 2019 Investor Conferences

GlobeNewswire August 29, 2019

Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity(TM) Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy

GlobeNewswire August 27, 2019

Mustang Bio and St. Jude Children's Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency (XSCID) granted regenerative medicine advanced therapy (RMAT) designation from FDA

GlobeNewswire August 22, 2019

Fortress Biotech Announces Appointment of Kevin L. Lorenz, J.D., to Board of Directors

GlobeNewswire August 19, 2019

Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2019

Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases

GlobeNewswire August 13, 2019

Mustang Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire August 9, 2019

Fortress Biotech Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire August 9, 2019

Checkpoint Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire August 8, 2019

FDA Clears IND for Mustang Bio's MB-102 (CD123 CAR T)

GlobeNewswire August 5, 2019

Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors

GlobeNewswire August 1, 2019

Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Acute Myeloid Leukemia

GlobeNewswire July 24, 2019

Checkpoint Therapeutics Added to Russell 2000® Index

GlobeNewswire July 1, 2019

Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain

GlobeNewswire June 3, 2019

Mustang Bio and St. Jude Children's Research Hospital to Participate in Panel Discussion at Boston CEO 2019

GlobeNewswire May 23, 2019

Mustang Bio to Present at the Cell & Gene Therapy USA Congress 2019

GlobeNewswire May 13, 2019

Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire May 13, 2019

Fortress Biotech Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire May 10, 2019